Fiocruz
- Company typePrivate
- Founded1900
- HeadquartersRio De Janeiro, Brazil
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
Fiocruz firmographics
Firmographics- Name
- Fiocruz
- Legal name
- Fundação Oswaldo Cruz
- Website
- https://portal.fiocruz.br
- Company type
- Private
- Founded year
- 1900
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
Fiocruz industry classification
Industry- Product category
- Public Health Research & Biomanufacturing
- NAICS
- Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC)
- akta.pro secondary industries
- Travel & Tropical Disease Vaccines (HLAIAEAE), Immunization & Vaccine Access Partnerships (Global Vaccine Alliances) (HLAJAOAF), Infectious Disease POCT (Respiratory, STI, HIV, Sepsis) (HLAHAOAA)
Keywords
Where Fiocruz is headquartered
LocationHeadquarters
- HQ city
- Rio De Janeiro
- HQ country
- Brazil
- HQ region
- Latin America
Offices17 records
Markets served
Fiocruz business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain
Revenue model
- Public Health System Supply: Fiocruz receives government funding to produce vaccines, medications, and health technologies for Brazil's Unified Health System (SUS)
- Technology Transfer and Partnerships: Strategic partnerships with international biotech companies (WuXi Biologics, GC MS) for technology transfer and domestic production development
- Research Grants and International Funding: Funding from international organizations including WHO for training initiatives and regional health programs
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Fiocruz product offering
Product offeringCore offering
Fiocruz (Fundação Oswaldo Cruz) is a Brazilian public health research institution that conducts biomedical, genomic, and clinical research across 16 technical-scientific units, manufactures vaccines and biopharmaceuticals through its Bio-Manguinhos and Farmanguinhos divisions, operates a national genomic surveillance network (Rede Genômica Fiocruz), provides respiratory and infectious disease surveillance platforms (InfoGripe, Observatório Covid-19), and delivers health-focused education and training programs through Campus Virtual Fiocruz and the Canal Saúde media outlet.
Product overview
Fiocruz (Fundação Oswaldo Cruz) is Brazil's premier public health institution operating as a complex ecosystem of 16 technical-scientific units focused on teaching, research, innovation, healthcare assistance, technological development, and extension services. The institution functions as a vertically integrated health system combining vaccine and pharmaceutical manufacturing (Bio-Manguinhos and Farmanguinhos), genomic surveillance (Rede Genômica Fiocruz), epidemiological monitoring platforms (InfoGripe, Observatório Covid-19), scientific computing infrastructure (PROCC), health data analytics (PCDAS), and educational platforms (Campus Virtual Fiocruz). The portfolio also includes science communication through Canal Saúde, Editora Fiocruz publishing, and the Museu da Vida science museum. Regional institutes extend Fiocruz's presence across Brazil (Fiocruz Amazônia, Fiocruz Minas, Fiocruz Pernambuco, Fiocruz Paraná) and internationally (Fiocruz África).
Differentiator
Problem solved
Functional benefit
Brands
- Bio-Manguinhos: Instituto de Tecnologia em Imunobiológicos - produces vaccines and immunobiologicals
- Farmanguinhos
- Campus Virtual Fiocruz
- Museu da Vida Fiocruz
- Canal Saúde
- Editora Fiocruz
Products and services
- Bio-Manguinhos (Vaccine Manufacturing) Manufactures vaccines and biologics (including Yellow Fever and COVID-19 vaccines) for distribution through Brazil's public health system (SUS) and through technology transfer partnerships with international manufacturers.
- Farmanguinhos (Pharmaceutical Production) Manufactures essential medicines, antiretrovirals, and other pharmaceutical products for the Brazilian public health system.
- Rede Genômica Fiocruz (Genomic Surveillance Network) Coordinates a national network for genomic surveillance of pathogens, including SARS-CoV-2, providing sequencing capacity and epidemiological intelligence to Brazil's public health authorities.
- InfoGripe (Respiratory Infection Surveillance) Public surveillance platform monitoring severe acute respiratory infections (SARIs) and influenza-like illness across Brazil, providing data to public health authorities and the general public.
- Campus Virtual Fiocruz Online learning platform delivering health-focused specializations, open courses, MOOCs, and training programs for health professionals, researchers, and the general public.
- Observatório Covid-19 Fiocruz Epidemiological observatory that tracks COVID-19 hospitalizations, severe acute respiratory infections, vaccination coverage, and other pandemic indicators across Brazil.
- Instituto Nacional de Infectologia Evandro Chagas (INI) National reference institute providing clinical care, clinical research, and training in infectious diseases including HIV/AIDS, tuberculosis, viral hepatitis, and tropical diseases.
- Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira (IFF) National reference hospital, research, and teaching institute specialized in women's, children's, and adolescent health, offering clinical services and residency programs.
- Banco de Leite Humano (Human Milk Bank Network) National reference center and network for human milk banking, supporting neonatal intensive care units across Brazil with pasteurized donor human milk and lactation support.
- Instituto Nacional de Controle de Qualidade em Saúde (INCQS) National reference laboratory providing quality control testing and analytical services for medicines, vaccines, diagnostic kits, cosmetics, sanitizers, and other health products in Brazil.
- Canal Saúde Television, web, and social media channel producing and broadcasting public health content, documentaries, and educational programming.
- Editora Fiocruz Academic publishing house producing scientific books, textbooks, and journals in public health, biomedical sciences, and the history of science.
- Museu da Vida Fiocruz Interactive science museum offering exhibits, educational programs, and science communication activities to promote public understanding of science and health.
- VideoSaúde Distribuidora Distribution service for audiovisual public health content, providing videos, documentaries, and educational materials to broadcasters, educators, and researchers.
Quantifiable outcome
- WHO designated as regional biomanufacturing training center for the Americas
- +2 more outcomes
Companies that use Fiocruz
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Fiocruz technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Fiocruz partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and major.
- World Health Organization (WHO)coreWHO designated Fiocruz as the regional biomanufacturing training center for the Americas, part of the WHO Biomanufacturing Workforce Training Initiative launched in 2023. The designation aims to support sustainable regional manufacturing capacity for health technologies across the Americas by training workforces in biomanufacturing skills.
- Pontificia Universidad Católica de Chile (UC Chile)majorJoint 12-month research project titled 'Enhancing Pathology through Quantum Computing' to develop hybrid quantum algorithms for biomedical image analysis using quantum machine learning and NVIDIA CUDA-Q platform. Project focuses on renal pathology and involves researchers from Fiocruz and UFBA.
- Thermo Fisher ScientificmajorFiocruz and Thermo Fisher Scientific signed memorandum of understanding to impulsionar inovação (drive innovation) in health sector through technology access and collaboration.
- BeOnemajorFiocruz and BeOne signed memorandum of understanding to impulsionar innovation in health. The agreement creates the basis for constructing solutions for complex health challenges.
- PfizermajorPartnership between Pfizer Inc and Fiocruz in Brazil for the tofacitinib market, part of global pharmaceutical collaborations targeting the Brazilian market.
- WuXi BiologicscoreFiocruz and Chinese biotech company WuXi Biologics signed a memorandum of understanding focused on creating technological capabilities and strengthening Brazil's health industrial base. The agreement was formalized during an official mission to China led by Minister of Health Alexandre Padilha.
- GEMMABiocorePublic-private partnership for gene therapy clinical trials for Spinal Muscular Atrophy Type 1 (SMA1) using GB221 therapy. The trial is being conducted in Brazil through a public-private partnership with Fiocruz, with ANVISA approval obtained in late 2025. US FDA granted rare pediatric disease designation.
- GC MS (GC Biopharma)majorGC MS, a subsidiary of GC Biopharma's in vitro diagnostics division, signed an MoU with Fiocruz at the Korea-Brazil Business Forum. The partnership aims to jointly develop reagents and transfer technology in immunology and biochemistry diagnostics, establish point-of-care testing solutions, and create new products.
- China (Ministry/Health Institutions)coreBrazil and China signed MoU in Beijing to expand medical research and treatment options in Brazil's public health system (SUS). Includes developing therapies for cancer, obesity, diabetes, and autoimmune diseases, and aims to produce insulin glargine domestically in Brazil.
- Birmex (Mexico)coreBrazil and Mexico signed dual MoUs in August 2025 establishing a regulatory and production alliance. Birmex and Fiocruz will jointly produce vaccines, pharmaceutical ingredients, and treatments including dengue therapies and mRNA vaccine technology. Initiative seeks to reduce dependence on external supply chains and strengthen health sovereignty.
- UN FoundationmajorUN Foundation, National Academy of Medicine, Fiocruz, and Global Pandemic Monitoring Board co-convened workshop on pandemic risk assessment intersecting with climate change in Rio de Janeiro, Brazil. Part of efforts to advance pandemic risk assessment frameworks.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
Fiocruz competitors and assessment
Company assessmentDirect peers
- Birmex: Mexico's state-owned biological and reagent laboratories, designated as Fiocruz's partner for joint vaccine and pharmaceutical production under the Brazil-Mexico alliance. Both are public-sector vaccine/biologic manufacturers serving national health systems with analogous institutional profiles.
- Instituto Butantan: Brazil's other major public-sector vaccine and biopharmaceutical producer, operating under the São Paulo state government. Directly comparable as a domestic public health manufacturer competing with Fiocruz in supplying SUS with vaccines, antivenoms, and biologics.
- Bio-Manguinhos (sub-brand): Fiocruz's own immunobiologicals institute, but operationally comparable to standalone public-sector vaccine manufacturers like Instituto Butantan and Bharat Biotech in scale, technology platform, and public health supply mandate.
Broad incumbents
- National Institutes of Health (NIH): US federal agency conducting and supporting biomedical and public health research at massive scale. Comparable as the largest government-funded public health research enterprise, with analogous structure of research institutes, training programs, and international cooperation activities.
- Pasteur Institute: French non-profit foundation and global reference public health research institution with comparable mandate across infectious disease research, vaccine development, epidemiological surveillance, and international training — a structurally similar public health foundation operating across multiple countries.
- Centers for Disease Control and Prevention (CDC): US federal public health agency with comparable mandate in infectious disease surveillance, epidemiological monitoring (parallel to InfoGripe and Rede Genômica), and global health partnerships through WHO/PAHO frameworks.
- Serum Institute of India: World's largest vaccine manufacturer by doses, supplying global immunization programs including low- and middle-income countries. Comparable as a high-volume, public-health-oriented vaccine producer, though structured as a private company rather than government foundation.
- China National Center for Disease Control and Prevention: China's national public health agency with parallel functions in disease surveillance, vaccine policy, and biomanufacturing oversight. Comparable as a counterpart public health authority and increasingly a partner institution through the MoU on insulin glargine production.
Regional players
- South African Medical Research Council (SAMRC): South Africa's statutory body for health research funding and coordination, with comparable mandate in biomedical research capacity building for an African context. Relevant given Fiocruz's Fiocruz África initiative and emerging Africa cooperation portfolio.
- Indian Council of Medical Research (ICMR): India's apex public health research body coordinating biomedical research, vaccine development, and infectious disease surveillance across a population of 1.4B. Comparable to Fiocruz as a government-funded public health research umbrella, though larger in scope and operating in a different geography.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Fiocruz social profiles
Digital presenceFiocruz financial estimates
Financial estimateRevenue estimate
Valuation estimate
Fiocruz leadership team
Management profileNumber of profiles
Fiocruz subsidiaries and ownership
Company hierarchySubsidiaries15 records
Fiocruz funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Fiocruz M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Fiocruz
What does Fiocruz do?
Fiocruz (Fundação Oswaldo Cruz) is a Brazilian public health research institution that conducts biomedical, genomic, and clinical research across 16 technical-scientific units, manufactures vaccines and biopharmaceuticals through its Bio-Manguinhos and Farmanguinhos divisions, operates a national genomic surveillance network (Rede Genômica Fiocruz), provides respiratory and infectious disease surveillance platforms (InfoGripe, Observatório Covid-19), and delivers health-focused education and training programs through Campus Virtual Fiocruz and the Canal Saúde media outlet.
Is Fiocruz a public or private company?
Fiocruz is a private company. It is classified as state government owned and is currently operating.
When was Fiocruz founded?
Fiocruz was founded in 1900. It employs 1,001 to 5,000 people.
Where is Fiocruz based?
Fiocruz is headquartered in Rio De Janeiro, Brazil, in the Latin America region.
How does Fiocruz make money?
Three revenue lines are on record. Public Health System Supply is the primary driver. The others are technology Transfer and Partnerships and research Grants and International Funding.
Who are Fiocruz's main competitors?
Direct peers on record are Birmex, Instituto Butantan and Bio-Manguinhos (sub-brand). Broad incumbents are National Institutes of Health (NIH), Pasteur Institute, Centers for Disease Control and Prevention (CDC), Serum Institute of India and China National Center for Disease Control and Prevention. Regional players are South African Medical Research Council (SAMRC) and Indian Council of Medical Research (ICMR).
Does Fiocruz have an API?
No public API is recorded for Fiocruz.
What industry is Fiocruz in?
Fiocruz's product category is Public Health Research & Biomanufacturing. Its primary akta.pro industry code is HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels), with a secondary code of HLAIAEAE, Travel & Tropical Disease Vaccines. Its NAICS code is 6215 and its SIC code is 2836.